Sirius Therapeutics launches SRSD107 Phase 1 trial, targeting thromboembolic disorders
Sirius Therapeutics, a pioneering biotechnology firm, has marked a significant milestone in the development of novel treatments for cardiovascular diseases by dosing the first subject in a Phase 1, first-in-human clinical trial of SRSD107 in Australia. SRSD107, a next-generation siRNA therapeutic, targets coagulation Factor XI (FXI) and is designed for the prevention and treatment of […]